Compare AIRG & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIRG | ACET |
|---|---|---|
| Founded | 1995 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 77.3M |
| IPO Year | 2016 | 2017 |
| Metric | AIRG | ACET |
|---|---|---|
| Price | $6.30 | $8.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $6.25 | ★ $48.33 |
| AVG Volume (30 Days) | ★ 77.8K | 65.8K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.65 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $51,779,000.00 | N/A |
| Revenue This Year | $10.31 | N/A |
| Revenue Next Year | $20.71 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.00 | $0.46 |
| 52 Week High | $7.66 | $9.47 |
| Indicator | AIRG | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 40.61 | 59.45 |
| Support Level | $3.90 | $7.02 |
| Resistance Level | $7.33 | $8.93 |
| Average True Range (ATR) | 0.30 | 0.38 |
| MACD | -0.07 | 0.08 |
| Stochastic Oscillator | 21.95 | 94.27 |
Airgain Incs a provider of advance wireless connectivity solutions. It is focused on delivering high-performance, cost-effective, and energy-efficient wireless solutions that enable rapid market deployment. It mission is to connect the world through integrated, and optimized wireless solutions. Companies' diverse product portfolio serves three primary markets: enterprise, automotive, and consumer. While historically recognized for high-performance radio frequency (RF) components, Airgain is increasingly delivering integrated, system-level connectivity solutions that combine hardware, software, and cloud management. The enterprise market demands reliable wireless access across diverse settings, including smart cities, campuses, stadiums, transportation hubs, utilities, buildings suburbs.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).